DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced it received the CE Mark for its intra-aortic balloon (IAB) and iPulse™ console platform. CE Mark approval allows this new combination console and disposable balloon to be sold in all European Union countries as well as many other countries worldwide that accept this approval for registration. Abiomed’s IAB is an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart function. The iPulse combination console platform drives Abiomed’s IAB, BVS 5000 and AB5000 Circulatory Support Systems, as well as new product introductions planned by Abiomed in the future. The iPulse is also designed to be compatible with other Original Equipment Manufacturer’s (OEMs) balloons.
